Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)

Inclusion Criteria:

• COVID-19 PCR positive,

• Hospitalized patients with illness of any duration, and/or SpO2 ≤ 92% on room air.

• Cohorte C : patients with cancer (hematological malignancies and solid tumors).

Exclusion Criteria:

• Refusal to participate,

• Any immunosuppressive therapy (i.e. corticosteroids >10mg of hydrocortisone orequivalent dose) within 14 days before the planned start of study,

• Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients),or a known history of active Tuberculosis bacillus,

• Active autoimmune disease that required a systemic treatment, with the followingexceptions:

• Patients with a history of autoimmune-related hypothyroidism who are on thyroidreplacement hormone are eligible for the study,

• Patients with controlled Type 1 diabetes mellitus who are on an insulin regimenare eligible for the study,

• Prior allogeneic bone marrow transplantation or prior solid organ transplantation,

• Patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-PD-1,anti-PD-L1, or anti-CTLA4 agent or any immune therapy or biotherapy (except forpatients in cohort C),

• Previous prescribing of biotherapy or treatment for the management of COVID-19 is notan exclusion criterion,

• Patient under guardianship, curatorship or under the protection of justice.